A1 Journal article – refereed
Serum Metabolites Associated with Computed Tomography Findings after Traumatic Brain Injury

List of Authors: Dickens AM, Posti JP, Takala RSK, Ala-Seppala H, Mattila I, Coles JP, Frantzen J, Hutchinson PJ, Katila AJ, Kyllonen A, Maanpaa HR, Newcombe V, Outtrim J, Tallus J, Carpenter KLH, Menon DK, Hyotylainen T, Tenovuo O, Oresic M, Oresic M
Publication year: 2018
Journal: Journal of Neurotrauma
Journal name in source: JOURNAL OF NEUROTRAUMA
Journal acronym: J NEUROTRAUM
Volume number: 35
Issue number: 22
Number of pages: 11
ISSN: 0897-7151
eISSN: 1557-9042

There is a need to rapidly detect patients with traumatic brain injury (TBI) who require head computed tomography (CT). Given the energy crisis in the brain following TBI, we hypothesized that serum metabolomics would be a useful tool for developing a set of biomarkers to determine the need for CT and to distinguish among different types of injuries observed. Logistical regression models using metabolite data from the discovery cohort (n=144, Turku, Finland) were used to distinguish between patients with traumatic intracranial findings and those with negative findings on head CT. The resultant models were then tested in the validation cohort (n=66, Cambridge, United Kingdom). The levels of glial fibrillary acidic protein and ubiquitin C-terminal hydrolase-L1 were also quantified in the serum from the same patients. Despite there being significant differences in the protein biomarkers in patients with TBI, the model that determined the need for a CT scan validated poorly (area under the curve [AUC]=0.64: Cambridge patients). However, using a combination of six metabolites (two amino acids, three sugar derivatives, and one ketoacid) it was possible to discriminate patients with intracranial abnormalities on CT and patients with a normal CT (AUC=0.77 in Turku patients and AUC=0.73 in Cambridge patients). Further, a combination of three metabolites could distinguish between diffuse brain injuries and mass lesions (AUC=0.87 in Turku patients and AUC=0.68 in Cambridge patients). This study identifies a set of validated serum polar metabolites, which associate with the need for a CT scan. Additionally, serum metabolites can also predict the nature of the brain injury. These metabolite markers may prevent unnecessary CT scans, thus reducing the cost of diagnostics and radiation load.

Last updated on 2019-21-08 at 22:36